No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
www.kexing.comNo one on the platform currently holds 688136.SS.
No tracked institution reports a position in 688136.SS as of their last filing.
No one on the platform has traded 688136.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.1% | — | — | — | ||
| Rev. Growth % | 9.5% | 4.8% | ||||
| Profit Margin % | 10.3% | -0.4% | ||||
| Free Cash Flow Margin % | 0.2% | -15.9% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.5B | -10.4% | $0.62 | $0.62–$0.62 | — | 1 |
| 2027 | $1.8B | +18.0% | $0.84 | $0.84–$0.84 | — | 1 |
| 2028 | $2.0B | +8.0% | $1.12 | $1.12–$1.12 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 688136.SSKexing Biopharm Co., Ltd. | $19.75 | +2.17% | $3.9B | — |
| 000990.SZChengzhi Shareholding Co., Ltd. | $6.47 | +1.89% | $11.0B | — |
| 002038.SZBeijing SL Pharmaceutical Co., Ltd. | $5.57 | +0.00% | $5.7B | — |
| 002275.SZGuilin Sanjin Pharmaceutical Co., Ltd. | $12.12 | -0.16% | $7.1B | — |
| 002940.SZZhejiang AngLiKang Pharmaceutical CO.,LTD. | $22.73 | +0.04% | $4.5B | — |
| 300705.SZHunan Jiudian Pharmaceutical Co., Ltd. | $10.44 | -0.38% | $5.2B | — |
| 603229.SSZhejiang Ausun Pharmaceutical Co., Ltd. | $7.55 | -0.13% | $6.3B | — |
Source: Financial Modeling Prep · peers by sector/industry